Major European Consensus Redefines Safe Use of GLP-1 Weight Loss Drugs
Leading European obesity bodies issue landmark guidance on nutrition, muscle preservation, and mental health during GLP-1 therapy.
Summary
A consensus statement from EASO, EFAD, and ECPO addresses critical gaps in managing adults on incretin-based therapies like GLP-1 receptor agonists. While these drugs deliver remarkable weight loss and cardiometabolic benefits, they also raise concerns about muscle loss, nutritional deficiencies, gastrointestinal side effects, and psychological shifts. The statement recommends adequate protein intake, progressive resistance training, micronutrient monitoring, and psychological screening as core components of care. It also calls for shared decision-making around dosing and emphasizes equitable access. Future research priorities include longitudinal micronutrient tracking, dietary pattern changes, musculoskeletal outcomes, and strategies for maintaining weight loss after stopping therapy.
Detailed Summary
Incretin-based therapies — including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide — have rapidly become first-line treatments for obesity, delivering unprecedented weight loss and reducing cardiovascular risk. Yet their widespread adoption has outpaced clinical guidance on managing the nutritional, functional, and psychological consequences of rapid, appetite-suppressed weight loss.
This consensus statement, jointly produced by the European Association for the Study of Obesity (EASO), the European Federation of the Associations of Dietitians (EFAD), and the European Coalition for People Living with Obesity (ECPO), synthesizes current evidence and offers pragmatic, clinician-ready recommendations across multiple domains of care.
On nutrition, the statement highlights the risk of inadequate protein intake and micronutrient deficiencies during rapid weight loss, recommending dietary quality monitoring and targeted protein goals. Gastrointestinal adverse effects — nausea, vomiting, reduced appetite — can further compromise nutritional status and require proactive management strategies.
On physical function, the authors emphasize that fat-free mass preservation is a critical and often overlooked concern. They recommend progressive resistance exercise alongside adequate protein intake as the primary strategy to maintain muscle mass and functional capacity during treatment.
Psychological dimensions receive significant attention, including shifts in food reward and coping behaviors, changes in social identity around eating, and the emotional complexity of body transformation. The statement recommends routine psychological screening and integrated mental health support where appropriate. It also addresses healthcare equity, urging systems to reduce disparities in access and adherence. Finally, it calls for robust longitudinal research on micronutrient status, dietary behavior change, musculoskeletal outcomes, and post-cessation weight maintenance to fill major evidence gaps.
Key Findings
- Adequate protein intake and resistance exercise are essential to preserve muscle mass during GLP-1-driven weight loss.
- Psychological risks including shifts in food reward and social identity require routine screening during incretin therapy.
- Micronutrient deficiency risk from reduced food intake warrants structured dietary monitoring throughout treatment.
- Shared decision-making on dosing — including pausing or stopping therapy — must weigh physical and psychological risks.
- Major research gaps remain in long-term micronutrient status, dietary patterns, and post-cessation weight maintenance strategies.
Methodology
This is a consensus statement developed by multidisciplinary expert panels from three major European organizations (EASO, EFAD, ECPO). It synthesizes existing evidence rather than presenting new primary data, and is published ahead of print in The Lancet Diabetes & Endocrinology in 2026.
Study Limitations
As a consensus statement based on available literature, recommendations reflect expert opinion where randomized trial evidence is limited or absent. Several identified research priorities — including longitudinal micronutrient data and post-cessation outcomes — remain understudied, limiting the strength of some guidance. Multiple authors declared financial relationships with Novo Nordisk and Eli Lilly.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: